tiprankstipranks
Trending News
More News >
Nanosonics Limited (AU:NAN)
ASX:NAN

Nanosonics Limited (NAN) AI Stock Analysis

Compare
39 Followers

Top Page

AU

Nanosonics Limited

(Sydney:NAN)

Rating:69Neutral
Price Target:
AU$5.00
▲(16.28%Upside)
Nanosonics Limited demonstrates strong financial health and positive earnings outlook, driven by robust revenue growth and strategic initiatives. However, technical analysis indicates bearish sentiment and potential overvaluation, which tempers the overall score. The company's performance is bolstered by effective cash management and growth prospects in its industry.

Nanosonics Limited (NAN) vs. iShares MSCI Australia ETF (EWA)

Nanosonics Limited Business Overview & Revenue Model

Company DescriptionNanosonics Limited, together with its subsidiaries, operates as an infection prevention company in Australia and internationally. The company engages in the manufacturing and distribution of the trophon ultrasound probe disinfector, and its associated consumables and accessories; and research, development, and commercialization of infection control and decontamination products and related technologies. It provides trophon2, an ultrasound probe high level disinfection device; trophon EPR, a low temperature high level disinfection solution for intra-cavity ultrasound probes; and Nanosonics AuditPro, an infection control workflow compliance management solution. Nanosonics Limited was incorporated in 2000 and is headquartered in Macquarie Park, Australia.
How the Company Makes MoneyNanosonics Limited generates revenue primarily through the sale and distribution of its trophon® EPR disinfection systems and related consumables. The company employs a razor-and-blades business model, where initial revenue is earned from selling the trophon® units, and ongoing revenue is derived from consumable items necessary for the system's operation, such as disinfectant cartridges and cleaning wipes. Additionally, Nanosonics benefits from service contracts and maintenance agreements, which provide a steady stream of income over time. The company also engages in partnerships and collaborations with healthcare organizations and equipment distributors to expand its market reach and drive sales growth.

Nanosonics Limited Earnings Call Summary

Earnings Call Date:Feb 19, 2025
(Q2-2025)
|
% Change Since: 24.28%|
Next Earnings Date:Sep 01, 2025
Earnings Call Sentiment Positive
The earnings call reflects a generally positive performance with substantial revenue growth, particularly in North America and Europe. While challenges exist in European installations and regulatory delays in Japan, the company's financial health and strategic region-focused growth remain strong.
Q2-2025 Updates
Positive Updates
Strong Revenue Growth
Revenue for H1 FY 2025 reached AUD 93.6 million, marking an 18% increase compared to the prior corresponding period and a 4% increase over the second half of FY 2024.
North American Market Success
The North American business saw significant growth with 940 new units installed, bringing the total to over 31,000 units. Annuity revenue growth in North America was 19%.
European Region Revenue Increase
Revenue in Europe grew by 37% compared to the prior corresponding period, reaching AUD 5.9 million.
Profitability and Operating Leverage
Profit before tax for the Trophon-only business was AUD 25.6 million, with PBT as a percentage of revenue growing from 23% to 27%.
Cash Flow and Financial Health
The business generated AUD 13.8 million in cash flow, leading to a cash balance of AUD 144.5 million, with no debt.
Gross Margin Improvement
Gross profit margin improved to 78.5%, up from 76.3% in the second half of 2024.
Negative Updates
Challenges in European Installations
The new installed base in Europe was slower than anticipated in H1 with only 70 units installed, though this is expected to improve in H2.
APAC Capital Revenue Decline
In APAC, capital revenue was down, although this was offset by a 14% increase in recurring annuity revenue.
Regulatory Delays in Japan
The guidelines for ultrasound probe disinfection in Japan are still not in place, affecting market penetration.
Company Guidance
During the Nanosonics Limited 2025 Half-Year Results call, the company provided updated guidance for the fiscal year. Revenue growth projections were increased from 8%-12% to 11%-14%, assuming an FX rate of $0.67, with potential for 13%-16% growth at a lower FX rate of $0.64. The North American market showed strong performance with 940 new trophon units installed, contributing to a total of over 31,000 units. Annuity revenue in North America grew by 19%, supported by customer value expansion and increased ultrasound procedures. In Europe, revenue grew by 37% to AUD 5.9 million despite slower-than-expected new installations. The APAC region saw a 14% increase in recurring annuity revenue, although capital revenue was down. The company also announced plans to commence consumables manufacturing at its Indianapolis site by the end of the financial year, aiming for margin improvements. Overall, the company anticipates growth across all regions, bolstered by strategic initiatives and operational performance.

Nanosonics Limited Financial Statement Overview

Summary
Income Statement
Balance Sheet
Cash Flow
Breakdown
Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
171.56M167.51M119.73M101.83M99.38M
Gross Profit
133.99M125.66M86.15M74.91M71.09M
EBIT
9.12M18.00M792.00K8.38M11.66M
EBITDA
21.72M29.50M7.86M15.75M16.70M
Net Income Common Stockholders
12.97M19.88M3.74M8.58M10.14M
Balance SheetCash, Cash Equivalents and Short-Term Investments
129.55M112.16M94.51M96.03M91.78M
Total Assets
237.34M226.07M193.24M164.57M148.23M
Total Debt
9.30M10.72M11.71M2.49M2.61M
Net Debt
-120.25M-101.44M-82.80M-93.54M-89.17M
Total Liabilities
55.14M62.22M54.55M29.01M24.00M
Stockholders Equity
182.20M163.86M138.69M135.57M124.23M
Cash FlowFree Cash Flow
20.27M19.74M-271.00K5.93M20.83M
Operating Cash Flow
22.78M23.31M6.70M7.32M22.76M
Investing Cash Flow
-2.36M-3.54M-6.90M-1.38M-1.94M
Financing Cash Flow
-3.01M-2.71M-1.97M-1.03M-1.30M

Nanosonics Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price4.30
Price Trends
50DMA
4.63
Negative
100DMA
4.29
Positive
200DMA
3.81
Positive
Market Momentum
MACD
-0.09
Positive
RSI
39.38
Neutral
STOCH
25.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NAN, the sentiment is Negative. The current price of 4.3 is below the 20-day moving average (MA) of 4.53, below the 50-day MA of 4.63, and above the 200-day MA of 3.81, indicating a neutral trend. The MACD of -0.09 indicates Positive momentum. The RSI at 39.38 is Neutral, neither overbought nor oversold. The STOCH value of 25.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:NAN.

Nanosonics Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AUSDI
76
Outperform
AU$101.04M9.5711.40%4.00%0.82%31.36%
AUAHC
75
Outperform
AU$111.04M11.1723.38%63.10%290.00%
AUNAN
69
Neutral
$1.32B78.759.23%10.79%5.20%
AUARX
54
Neutral
AU$177.62M-4.06%15.90%8.52%
54
Neutral
$5.31B3.29-45.39%2.79%16.77%-0.07%
AUTRJ
45
Neutral
AU$112.00M-24.66%0.70%-1600.91%
AUCYC
44
Neutral
AU$116.69M-35.20%4.68%-155.42%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:NAN
Nanosonics Limited
4.30
1.47
51.94%
AU:SDI
SDI Limited
0.85
0.08
10.39%
AU:AHC
Austco Healthcare Limited
0.30
0.11
57.89%
AU:CYC
Cyclopharm Limited
1.05
-0.53
-33.54%
AU:TRJ
Trajan Group Holdings Ltd
0.72
-0.20
-21.74%
AU:ARX
Aroa Biosurgery Ltd
0.52
-0.09
-14.75%

Nanosonics Limited Corporate Events

Nanosonics Addresses ASX Query on Unusual Trading Activity
May 21, 2025

Nanosonics Limited responded to a query from the Australian Securities Exchange (ASX) regarding unusual trading activity in its securities. The company stated that it is not aware of any undisclosed information that could explain the recent price and volume changes and confirmed compliance with ASX Listing Rules, particularly Rule 3.1, which pertains to continuous disclosure obligations.

The most recent analyst rating on (AU:NAN) stock is a Sell with a A$4.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.

Nanosonics CEO Adjusts Shareholdings to Address Tax Obligations
May 5, 2025

Nanosonics Limited announced a change in the director’s interest, with CEO Michael Kavanagh selling 100,000 ordinary shares to cover a tax liability from exercising company securities. Despite the sale, Kavanagh retains a significant holding of 1,256,723 shares and 1,569,840 rights, indicating continued confidence in the company’s prospects.

ECP Asset Management and EC Pohl & Co Cease Substantial Holding in Nanosonics Limited
Mar 25, 2025

Nanosonics Limited announced that ECP Asset Management Pty Ltd and EC Pohl & Co Pty Ltd have ceased to be substantial holders in the company as of March 21, 2025. This change in substantial holding could impact the company’s shareholder structure and influence its market positioning, potentially affecting investor perceptions and stakeholder interests.

Nanosonics Secures FDA Clearance for CORIS® System
Mar 19, 2025

Nanosonics Limited has received FDA De Novo clearance for its CORIS® system, a novel technology aimed at reducing infection risks and improving cleaning outcomes for flexible endoscopes. This clearance marks a significant milestone for the company, with plans for a commercial launch in Q1 FY26, initially targeting a controlled market release in select hospitals before a broader rollout.

Nanosonics Director Increases Shareholding, Signaling Confidence
Mar 14, 2025

Nanosonics Limited announced a change in the director’s interest, with Gerard Dalbosco acquiring 7,442 ordinary shares, bringing his total to 27,442 shares. This transaction, valued at $32,372.70, reflects continued confidence in the company’s market position and potential growth, potentially impacting stakeholders’ perception positively.

Nanosonics Limited Announces Quotation of New Securities
Mar 13, 2025

Nanosonics Limited has announced the application for quotation of 43,298 ordinary fully paid securities on the Australian Securities Exchange. This move is part of an employee incentive scheme and indicates the company’s ongoing efforts to incentivize its workforce, potentially impacting its operational dynamics and market position positively.

Nanosonics Updates on Director’s Interest Notice
Mar 12, 2025

Nanosonics Limited announced a change in the director’s interest notice due to an acquisition of performance rights by CEO Michael Kavanagh. The company acknowledged a delay in lodging the notice due to an administrative oversight and has since reviewed its procedures to ensure compliance with ASX listing rules.

Nanosonics Corrects Security Classification Error in Recent Announcement
Mar 12, 2025

Nanosonics Limited has issued an update to a previous announcement regarding the classification of securities. Initially reported as ordinary fully paid shares due to a selection error, the correct classification is NANAO Performance Rights, with 2,248,299 rights issued under the Nanosonics Employee Equity Plan. This correction clarifies the nature of the securities involved, which may impact stakeholders’ understanding of the company’s equity structure.

Nanosonics Director Acquires 20,000 Shares
Mar 11, 2025

Nanosonics Limited has announced a change in the director’s interest, with Gerard Dalbosco acquiring 20,000 ordinary shares in the company. This acquisition, valued at approximately $87,139.75, reflects a significant investment by the director, potentially indicating confidence in the company’s future performance and strategic direction.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.